Spotlight on Cardiovascular Disease: Outcomes following TAVR, LDL receptor status and diabetes risk, statin intolerance, NOAC dosing, and more.

Published: March 10, 2015, 3 p.m.

b"

Editor's Audio Summary by Eric D. Peterson, MD, MPH, Associate Editor, the Journal of the American Medical Association, for the March 10, 2015 issue

"